Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

NA-22598B1 and B2: novel anticancer compounds produced by Streptomyces

July 2, 1999

CRC selects water-soluble paclitaxel for phase I trial

July 2, 1999

CDK4-specific antisense oligodeoxynucleotides for inhibition of tumors

July 1, 1999

Coulter, SmithKline Beecham file BLA for Bexxar

July 1, 1999

5-Halo- or nitrate-substituted paclitaxels under study at Bristol-Myers Squibb

July 1, 1999

Alza's Doxil approved in U.S. for treatment of refractory ovarian cancer

July 1, 1999

Valentis moves IL-2 gene therapy to phase II

July 1, 1999

InKine files two patent applications relating to thrombospondin receptor

July 1, 1999

NCI initiates phase I trials with patient-specific cancer vaccines

July 1, 1999

Introgen Therapeutics receives milestone payment from RPR

July 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...